- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01294163
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
Efficacy and Safety of Xenon Anaesthesia Compared to Sevoflurane Anaesthesia and Total Intravenous Anaesthesia for On-pump Coronary Artery Bypass Graft Surgery: a Randomised, Three-arm, Single-blind, International Study
Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies. In animal studies, xenon decreases the size of experimental myocardial infarction.
This 3-arm study will compare xenon, sevoflurane and a propofol-based total intravenous anaesthesia for maintenance of anaesthesia during coronary artery bypass graft surgery conducted with extra-corporeal circulation. Xenon and sevoflurane will be administered before and after extracorporeal circulation. Propofol will be administered during extracorporeal circulation in the three groups of patients.
The study will compare the postoperative myocardial damage observed 24 hours after surgery from blood levels of troponin I, a largely accepted biomarker of myocardial necrosis. The main hypothesis is that the myocardial damage observed after xenon administration will not be superior to the damage observed after sevoflurane administration (non-inferiority). The second hypothesis is that the myocardial damage observed after xenon administration will be inferior to the damage observed after total intravenous anaesthesia.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69677
- Hopital Cardiovasculaire et Pneumologique Louis Pradel
-
Caen, France, 14033
- CHU de Caen
-
Nantes, France, 44093
- Hôpital G&R Laennec - Centre Hospitalier Universitaire de Nantes
-
Paris, France, 75013
- Centre Hospitalo-Universitaire Pitié-Salpetrière
-
Pessac, France, 33600
- Hopital Du Haut-Leveque
-
Rennes, France, 35033
- Hopital Pontchaillou
-
Strasbourg, France, 67091
- Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil
-
Toulouse, France, 31059
- Centre Hospitalier de Rangueil
-
-
-
-
-
Aachen, Germany, 52074
- University Hospital Aachen
-
Bremen, Germany, 28277
- Klinikum Links der Weser - Senator-Wessling-Str. 1
-
Frankfurt, Germany, 60590
- University Hospital Frankfurt am Main
-
Lubeck, Germany, 23538
- Universitätsklinikum Schleswig-Holstein
-
Rostock, Germany, 18057
- University Hospital Rostock
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Universitätsklinikum Schleswig-Holstein
-
-
-
-
-
Rome, Italy, 00161
- Policlinico Umberto I
-
-
-
-
-
Amsterdam, Netherlands, 1100 DD
- Academic Medical Center - University of Amsterdam
-
Rotterdam, Netherlands, 3000 CA
- Thorax Center - Erasmus MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- coronary artery disease
- elective surgery, planned coronary artery bypass graft
- moderate hypothermia or normothermia
- cardiac arrest cold and warm cardioplegia
- normal of moderately impaired left ventricular systolic function
- written informed consent
Exclusion Criteria:
- pregnancy or child bearing potential
- ongoing treatment with nicorandil or sulfonylurea medication
- severe renal or hepatic dysfunction
- ongoing myocardial infarction or unstable angina
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Xenon
|
Inhaled xenon, maximal inspired concentration of 65%.
|
Active Comparator: Sevoflurane
|
Inhaled sevoflurane, maximal inspired concentration of 1.8%.
|
Active Comparator: Total intravenous anaesthesia
|
Hourly dose of 2-4 mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Level of Troponin I
Time Frame: Sampling performed 24 hours after the end of the surgical procedure
|
Blood level of troponin I measured by a central laboratory
|
Sampling performed 24 hours after the end of the surgical procedure
|
Log-transformed Blood Level of Troponin I
Time Frame: Sampling performed 24 hours after the end of the surgical procedure
|
Blood level of troponin I measured by a central laboratory
|
Sampling performed 24 hours after the end of the surgical procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depth of Anaesthesia
Time Frame: 4 hours
|
On-line monitoring of depth of anaesthesia from bi-spectral electroencephalogram analysis (BIS monitor)
|
4 hours
|
Arterial Oxygen Saturation
Time Frame: 4 hours
|
Arterial blood gases
|
4 hours
|
Haemodynamic Profile
Time Frame: 4 hours
|
Monitoring of heart rate, arterial blood pressure, central venous pressure.
|
4 hours
|
Presence or Absence of Postoperative Delirium
Time Frame: 7 days
|
Confusion Assessment Method
|
7 days
|
Clinical Laboratory Tests
Time Frame: 7 days
|
7 days
|
|
ECG Abnormalities
Time Frame: 7 days
|
7 days
|
|
Vital Signs
Time Frame: 7 days
|
7 days
|
|
Presence of Absence of Adverse Events, Including Myocardial Infarction
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jan HOFLAND, MD, PhD, Thorax Centre Erasmus MC, Rotterdam, the Netherlands
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Hypersensitivity
- Drug-Related Side Effects and Adverse Reactions
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Drug Hypersensitivity
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Platelet Aggregation Inhibitors
- Hypnotics and Sedatives
- Anesthetics, Inhalation
- Propofol
- Sevoflurane
Other Study ID Numbers
- ALMED-09-C3-026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Xenon
-
University of Kansas Medical CenterJohns Hopkins University; M.D. Anderson Cancer Center; Baylor College of Medicine and other collaboratorsNot yet recruiting
-
University of Kansas Medical CenterAmerican Heart AssociationRecruitingPulmonary Arterial HypertensionUnited States
-
Air Liquide Santé InternationalCompleted
-
Cyclomedica Australia PTY LimitedTerminatedLung Structure DeterminationUnited States
-
University of VirginiaRecruitingChronic Obstructive Pulmonary DiseaseUnited States
-
University of VirginiaDuke UniversityRecruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustCompleted
-
Children's Hospital of PhiladelphiaRecruitingThoracic Insufficiency SyndromeUnited States
-
Oxford University Hospitals NHS TrustUniversity of Sheffield; National Institute for Health Research, United KingdomCompleted